<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/CCAFCFE5-4600-4CC7-A5C6-E2F86DD7A808" ns1:id="CCAFCFE5-4600-4CC7-A5C6-E2F86DD7A808"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/88AD02CA-2F8D-4D85-A187-483179EEEC4C" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/88AD02CA-2F8D-4D85-A187-483179EEEC4C" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/66B175B1-48DB-4EF1-905F-6EDE6FC212CF" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/EBBAC660-5B1B-4616-BFA7-163A63C34D09" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/6B57D64D-182B-4847-8A8F-366E0669D013" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2012-02-29T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/499BEB95-FDF5-44D4-A72B-D50F9D9CF59D" ns1:rel="FUND" ns1:start="2011-05-31T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">100961</ns2:identifier></ns2:identifiers><ns2:title>Production of Secondary Metabolites by Plant Cell Suspension Cultures (Metavesse)</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Collaborative R&amp;D</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Metavesse is a project which investigated the production of plant cell secondary metabolites derived from two specially selected plant cell lines. The cell lines were selected from amongst Evesse Apple vaieties based on their projected yield of (-)-epicatechin monomers and specific procyanidin oligomers. These cell lines are intended for use in cosmetics and cosmaceuticals. The first cell line was propagated to produce a clean and reproducible source of high levels of (-)-epciatechin and the second was propagated to produce specially identified molecules which had previously been shown to provide &amp;quot;surface&amp;quot; vasodilation and anti-cancer properties. The cell lines were used to produce standardised products which have been successfully characerised in terms of their anti-oxidant, cell necrosis and cell protection characteristics.</ns2:abstractText></ns2:project>